ReviewAnnals of clinical microbiology and antimicrobials2024
Clinical characteristics and drug resistance of Nocardia in Henan, China, 2017-2023.
Review in Annals of clinical microbiology and antimicrobials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 12 citations in OpenAlex.
- Bioaerosol assessment of indoor air in hospital wards for isolation ofNew microbes and new infections · 2026Article
- Pulmonary Nocardia otitidiscaviarum in immunocompetent individuals: a case series and literature review.BMC infectious diseases · 2026Review
- Research progress on clinical challenges and prevention strategies of drug-resistantFrontiers in public health · 2026Review
- Multiple Deep Abscesses Caused by DisseminatedInfection and drug resistance · 2026Article
- Bridging the gap in nocardiosis treatment: the promise of nanoparticle-based antimicrobials.Annals of medicine and surgery (2012) · 2026Article
- Clinical characteristics of pulmonary nocardiosis in patients with and without bronchiectasis: a single-center retrospective comparative study.Frontiers in cellular and infection microbiology · 2026Article
- When metagenomic next-generation sequencing detectsFrontiers in cellular and infection microbiology · 2026Article
- Epidemiology, clinical treatment and outcomes, susceptibility patterns and genotypic analysis of 214Frontiers in cellular and infection microbiology · 2026Article
- Antibiotic Susceptibility ofChina CDC weekly · 2025Article
- Chronic renal insufficiency andWorld journal of clinical cases · 2025Article
- SLE complicated with Nocardia farcinica bloodstream infection and disseminated nocardiosis: a case report.BMC infectious diseases · 2025Article
- Genomic characteristics, virulence potential, antimicrobial resistance profiles, and phylogenetic insights into Nocardia cyriacigeorgica.Annals of clinical microbiology and antimicrobials · 2025Article
- Genomic and phenotypic characterization of antimicrobial resistance in clinicalFrontiers in cellular and infection microbiology · 2025Article
- Severe pneumonia caused byFrontiers in medicine · 2025Article
- The first known case of Nocardia wallacei infection in Cyprus.GMS hygiene and infection control · 2025Article
- Diagnostic model for COPD patients with nocardia infection: a study based on clinical features and risk factors.Therapeutic advances in respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe aim of this study was to investigate the clinical features of Nocardia infections, antibiotic resistance profile, choice of antibiotics and treatment outcome, among others. In addition, the study compared the clinical and microbiological characteristics of nocardiosis in bronchiectasis patients and non-bronchiectasis patients.
methodsDetailed clinical data were collected from the medical records of 71 non-duplicate nocardiosis patients from 2017 to 2023 at a tertiary hospital in Zhengzhou, China. Nocardia isolates were identified to the species level using MALDI-TOF MS and 16S rRNA PCR sequencing. Clinical data were collected from medical records, and drug susceptibility was determined using the broth microdilution method.
resultsOf the 71 cases of nocardiosis, 70 (98.6%) were diagnosed as pulmonary infections with common underlying diseases including bronchiectasis, tuberculosis, diabetes mellitus and chronic obstructive pulmonary disease (COPD). Thirteen different strains were found in 71 isolates, the most common of which were N. farcinica (26.8%) and N. cyriacigeorgica (18.3%). All Nocardia strains were 100% susceptible to both TMP-SMX and linezolid, and different Nocardia species showed different patterns of drug susceptibility in vitro. Pulmonary nocardiosis is prone to comorbidities such as bronchiectasis, diabetes mellitus, COPD, etc., and Nocardia is also frequently accompanied by co-infection of the body with pathogens such as Mycobacterium and Aspergillus spp. Sixty-one patients underwent a detailed treatment regimen, of whom 32 (52.5%) received single or multi-drug therapy based on TMP-SMX. Bronchiectasis was associated with a higher frequency of Nocardia infections, and there were significant differences between the bronchiectasis and non-bronchiectasis groups in terms of age distribution, clinical characteristics, identification of Nocardia species, and antibiotic susceptibility (P < 0.05).
conclusionsOur study contributes to the understanding of the species diversity of Nocardia isolates in Henan, China, and the clinical characteristics of patients with pulmonary nocardiosis infections. Clinical and microbiologic differences between patients with and without bronchiectasis. These findings will contribute to the early diagnosis and treatment of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.